Lornoxicam Tablets Suppliers & Bulk Manufacturers
Available Forms: Oral Tablets
Available Strengths: 4 mg, 8 mg
Reference Brands: Xefo (EU)
Category:
Analgesic
Lornoxicam inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis responsible for pain and inflammation. Benefits include rapid, effective relief from acute pain, inflammation, and rheumatologic conditions. It offers anti-inflammatory, analgesic effects with a favorable safety profile when used appropriately.
Lornoxicam tablets is available in Oral Tablets
and strengths such as 4 mg, 8 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Lornoxicam tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Lornoxicam tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Lornoxicam tablets are approved in the EU for managing pain and inflammation, regulated by EMA with dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, lornoxicam is not approved and is not marketed. In the EU, brands like Xefo (by Orion) are supported by comprehensive clinical data, with ongoing pharmacovigilance. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support efficient market access for lornoxicam tablets, ensuring adherence to European standards for safe, effective pain management, helping you navigate complex regulatory pathways seamlessly.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing